Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the last patient has been dosed in its Phase 1b pharmacoscintigraphic study of CP-012. CP-012 is a novel delayed-release, dual-pulse levodopa/carbidopa tablet developed to address the debilitating challenges of nocturnal immobility and early morning akinesia in patients with Parkinson’s disease.

“The completion of dosing in this Phase 1b study is an important step forward in the clinical development of CP-012,” said Anne Birk Østerskov, CMO of Contera Pharma. “We are eager to analyze the data and further validate the potential of CP-012 to deliver levodopa/carbidopa at the times when patients need it most. If successful, CP-012 could become a much-needed treatment option for nocturnal and early morning motor complications that significantly impair quality of life for people living with Parkinson’s disease.”

“Reaching last-patient-dosed is a critical milestone for our CP-012 program. We are grateful to the patients and investigators for their participation, and we look forward to reporting topline results from this study later this year. This progress reinforces our mission to advance innovative therapies that address the unmet needs of Parkinson’s patients worldwide.”

About the study
The Phase 1b exploratory pharmacoscintigraphic study is a single centre, open-label, crossover trial in up to 15 Parkinson’s disease patients. Its primary objective is to evaluate the absorption (PK) of levodopa and carbidopa from two novel delayed pulsatile release CP-012 formulations and correlate these findings with scintigraphic data on time and site of release. The study is conducted in collaboration with BDD Pharma at their clinical site in Glasgow, Scotland.

About morning akinesia and nocturnal immobility
Early morning akinesia (morning OFF episodes) affects around 60-70% of Parkinson’s disease patients across all disease stages, often accompanied by non-motor symptoms such as anxiety, depression, pain, and urinary urgency. Nocturnal immobility is similarly common and contributes to poor sleep quality and reduced overall quality of life. Despite their prevalence, effective and easy-to-use treatment options remain lacking, leaving a significant unmet medical need.

About Contera Pharma A/S
Contera Pharma A/S is focused on developing novel treatments for people suffering from neurological disorders. Contera Pharma’s science is based on a precision medicine approach integrating external and internal data sources to support rational selection of human disease-validated drug discovery targets to identify novel pipeline opportunities within neurological disorders. CP-012 is an investigational drug that is not approved for use by any regulatory authorities. Contera Pharma has full ownership and holds global rights to the CP-012 program (Contera Pharma holds a license to BDD Pharma’s OralogiK® formulation technology). Contera Pharma is based in Hørsholm, Denmark.

For more information, visit www.conterapharma.com